The RIGHT foundation is pleased to announce new funding opportunities: Product Development Award (PDA) Targeted Calls (Monoclonal Antibodies (mAbs)/ Diagnostics for STIs) on top of the open call. The PDA General call will continue to accept proposals on a rolling basis, and the Targeted calls will seek proposals on two specified topics during a fixed period. Detailed information can be found in the Request for Proposal (RfP) documents linked below.
Overview of RfPs
| PDA General Call | PDA Targeted Call for mAbs | PDA Targeted Call for STI Diagnostics | |
|---|---|---|---|
| Description | PDA General call seeks proposals aimed at developing vaccines, therapeutics, biologics, or diagnostic platforms, including technology transfer of target intervention from or to a Korean partner to alleviate infectious diseases in the World Bank-defined low- and middle-income countries (LMICs). | PDA Targeted call for Monoclonal Antibodies seeks proposals to validate novel technologies to lower the costs of producing/manufacturing mAbs to prevent and/or treat one of the three diseases: severe respiratory syncytial virus (RSV) disease, severe malaria, or diseases with a pandemic potential or viral pathogens with pandemic potential. | PDA Targeted call for STI Diagnostics seeks proposals that will accelerate development of and access to point-of-care diagnostic tests for high priority sexually transmitted infections (STIs): gonorrhoeae, chlamydia, trichomoniasis and syphilis. |
| Submission deadline for application | Until December 31, 2024, KST (on a rolling basis) |
Until 10:00 AM, May 27, 2024, KST | |
| Co-funding | Not Applicable | Not Applicable | FIND (See details and conditions below) |
| RfP / RfP instructions |
- RfP for PDA General Call - RfP Instructions for PDA General Call |
- RfP for PDA Targeted Call for mAbs - RfP Instructions for PDA Targeted Call for mAbs |
- RfP for PDA Targeted Call for STI Diagnostics - RfP Instructions for PDA Targeted Call for STI Diagnostics |
| Relevant documents |
- Grant Cost Guidance - How to submit your application (User manual for the Grant Management System) |
||
| Link for application submission | Click to start application | Click to start application | Click to start application |
Co-funding Opportunity with FIND
The PDA targeted call for STI diagnostics is released in coordination with FIND, an international non-profit organization focused on the development and delivery of priority diagnostic tests for poverty-related diseases. Applicants with proposals that meet FIND’s RfP criteria are encouraged to apply to both RIGHT and FIND for co-funding. The benefits of co-funding include increased project funding and access to FIND’s expertise in technical development, policy, and clinical care.
FIND Application Deadline: 06 May 2024
Co-funding eligibility: Proposals meet both RIGHT Foundation and FIND RfP eligibility criteria.
Terms and conditions:
- All proposals will be reviewed by RIGHT Foundation and FIND independently, and the selection status of one funder does not impact eligibility for funding by the other.
- Proposals may be selected for funding by RIGHT Foundation, FIND, or by both funders.
- RIGHT Foundation reserves the right to fund all or up to 50% of the total requested funding for proposals of interest to RIGHT independently of FIND.
- Successful applicants will be awarded funding for two-thirds of total project costs (i.e. one-third contributions from each of RIGHT Foundation, FIND, and grantee) or up to the maximum award amount of each funder, respectively.
- FIND offers both funding and in-kind support to grantees. Applicants may elect to propose a technical partnership with FIND.
Applicants interested in being evaluated for co-funding by FIND should submit applications to FIND by 06 May 2024. The RfP can be found on the FIND website under “Request for proposals (RFP) for manufacturers of true point-of-care molecular tests for Neisseria gonorrhoeae and Chlamydia trachomatis to accelerate product development/ evaluation and market entry in low- and middle- income countries”.
Evaluation timeline for PDA General Call
| ITA review date (ITAs received on a rolling basis) |
Notification of Full proposal invitation | Full proposal submission date1) | Technical evaluation of Full proposal by Panel of Experts | Technical evaluation by Selection committee2) | Funding decision by the Board of Directors | Grant Agreement negotiation notice |
|---|---|---|---|---|---|---|
| 1 Feb 2024 | 8 Feb 2024 | Early Apr 2024 | Apr-May 2024 | 2By late May 2024 | Early July 2024 | Mid July 2024 |
| 1 Apr 2024 | 9 Apr 2024 | Early Jun 2024 | Jun-Jul 2024 | By early Sept 2024 | Late Nov 2024 | End Nov 2024 |
| 1 June 2024 | 10 Jun 2024 | Early Aug 2024 | Aug-Sept 2024 | By Oct 2024 | Late Nov 2024 | End Nov 2024 |
| 1 August 2024 | 9 Aug 2024 | Early Oct 2024 | Oct-Nov 2024 | By Jan 2025 | Late Feb 2025 | End Feb 2025 |
| 1 Oct 2024 | 10 Oct 2024 | Early Dec 2024 | Dec 2024-Jan 2025 | By late Mar 2025 | Late Apr 2025 | End Apr 2025 |
Evaluation timeline for PDA Targeted Call (mAbs/ STI Diagnostics)
| ITA submission deadline | Notification of Full proposal invitation | Full proposal submission date1) | Technical evaluation of Full proposal by Panel of Experts | Technical evaluation by Selection committee2) | Funding decision by the Board of Directors | Grant Agreement negotiation notice |
|---|---|---|---|---|---|---|
| 10:00 AM, 27 May 2024, KST | Early June 2024 | Early July 2024 | July-August 2024 | By early September 2024 | October 2024 | End October 2024 |
Orientation sessions for the PDA Targeted Call
The three orientation sessions for the PDA targeted call will be held to discuss the funding scope, the application process, and to answer questions on the following schedules. The three orientations will be identical, but different languages and schedules. Please click to register for the orientation session below.